Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics.
BACKGROUND
A large study on the safety of biologics required pooling of data from multiple data sources, but while extensive confounder adjustment was necessary, private, individual-level covariate information could not be shared.


OBJECTIVE
To describe the methods of pooling data that investigators considered, and to detail the strengths and limitations of the chosen method: a propensity score (PS)-based approach that allowed for full multivariate adjustment without compromising patient privacy.


METHODS
The project had a central data coordinating center responsible for collection and analysis of data. Private data could not be transmitted to the data coordinating center. Investigators assessed 4 methods for pooled analyses: full covariate sharing, cell-aggregated sharing, meta-analysis, and the PS-based method. We evaluated each method for protection of private information, analytic integrity and flexibility, and ability to meet the study's operational and statistical needs.


RESULTS
Analysis of 4 example datasets yielded substantially similar estimates if data were pooled with a PS versus individual covariates (0%-3% difference in point estimates). Several practical challenges arose. (1) PSs are best suited for dichotomous exposures but 6 or more exposure categories were desired; we chose a series of exposure contrasts with a common referent group. (2) Subgroup analyses had to be specified a priori. (3) Time-varying exposures and confounders required appropriate analytic handling including re-estimation of PSs. (4) Detection of heterogeneity among centers was necessary.


CONCLUSIONS
The PS-based pooling method offered strong protection of patient privacy and a reasonable balance between analytic integrity and flexibility of study execution. We would recommend its use in other studies that require pooling of databases, multivariate adjustment, and privacy protection.
Rassen
Jeremy A
JA
Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA. jrassen@post.harvard.edu
Solomon
Daniel H
DH
Curtis
Jeffrey R
JR
Herrinton
Lisa
L
Schneeweiss
Sebastian
S
D001688:Biological Products / Q000009:adverse effects*; D003219:Confidentiality; D003627:Data Interpretation, Statistical; D006801:Humans; D013997:Time Factors; D016896:Treatment Outcome
D001688:Biological Products
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Ann Intern Med. 1997 Oct 15;127(8 Pt 2):757-63
9382394
Biometrics. 1992 Jun;48(2):479-95
1637973
CMAJ. 2009 Mar 31;180(7):713-8
19176635
Med Care. 2010 Jun;48(6 Suppl):S83-9
20473213
Arthritis Rheum. 2008 Jun 15;59(6):762-84
18512708
Am J Epidemiol. 2006 Jun 1;163(11):1053-64
16624970
Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):2-9
19757416
Am J Epidemiol. 2003 Nov 1;158(9):915-20
14585769
JAMA. 2009 Mar 4;301(9):937-44
19258584
Epidemiology. 2009 Jul;20(4):512-22
19487948
Circulation. 2009 Dec 8;120(23):2322-9
19933932
J Am Coll Cardiol. 2008 Jan 22;51(3):256-60
18206732
Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):253-9
16611199
Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):848-57
20162632
Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):373-7
11802579
Epidemiology. 1996 Jul;7(4):335-6
8793355
Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1226-34
18956428